GSK and the University of Manchester in research alliance
This article was originally published in Scrip
GlaxoSmithKlineand the University of Manchester (UK) have signed an agreement to focus on research methodologies such as systems biology and biomedical imaging, and treatment areas such as respiratory diseases and inflammation processes. The deal will involve scientists and physicians working together to identify new research avenues, collaborate in efforts to better understand a variety of disease areas and support drug discovery within the UK, the university said. GSK has previously collaborated with many figures from the university, including Professor Doug Kell of the School of Chemistry, Professor Ashley Woodcock of the School of Translational Medicine and Professor David Ray of the School of Clinical and Laboratory Sciences. Any royalty or milestone payments associated with products developed in the alliance will be decided on a case-by-case basis, the university told Scrip.
You may also be interested in...
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.